扩展多变量模型辅助选择长效卡博特韦联合利匹韦林治疗患者:患者、药物浓度及病毒因素组合与病毒学失败的临床效用
该研究汇总1651名参与者数据,扩展多变量分析探索长效卡博特韦联合利匹韦林(CAB+RPV LA)确认病毒学失败(CVF)的预测因素。截至152周,CVF发生率为1.4%(23/1651)。RPV耐药相关突变、HIV-1 A6/A1亚型及BMI≥30 kg/m²与CVF风险升高相关(P<.05校正发病率比),≥2个基线因素者风险更高。
要点
- RPV耐药相关突变、HIV-1 A6/A1亚型及BMI≥30 kg/m²与CVF风险升高相关(P<.05校正发病率比)。
- 具备≥2个上述基线因素者CVF风险更高,与既往分析一致。
- 模型预测的CAB/RPV谷浓度(≤第一四分位数)未在≥2个基线因素组合之外改善CVF预测。
核心结论
- 具备≥2个基线因素(RPV耐药相关突变、A6/A1亚型及/或BMI≥30 kg/m²)与CVF风险升高相关,与既往分析一致。
- 纳入初始模型预测的CAB/RPV谷浓度(≤第一四分位数)未能在≥2个基线因素组合之外改善CVF预测,强化了基线因素在CAB+RPV LA合理使用中的临床效用。
研究设计与样本
- 汇总1651名参与者的数据,探索给药方案(每4周或每8周)、人口学、病毒学及药代动力学协变量作为CVF的潜在预测因素。
- 使用2个人群考虑既往给药方案经验,每个人群进行两项模型分析:基线因素分析探索基线已知因素,多变量分析探索基线因素加基线后模型预测的CAB/RPV谷浓度(注射后4周和44周)。
主要发现
- 截至152周,总体CVF发生率为1.4%(n=23/1651)。
- RPV耐药相关突变、HIV-1 A6/A1亚型及BMI≥30 kg/m²与CVF风险升高相关(P<.05校正发病率比)。
- 具备≥2个上述基线因素的参与者CVF风险更高。
- 较低的模型预测CAB/RPV谷浓度是多变量分析中保留的额外因素。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previously reported post hoc multivariable analyses exploring predictors of confirmed virologic failure (CVF) with cabotegravir + rilpivirine long-acting (CAB + RPV LA) were expanded to include data beyond week 48, additional covariates, and additional participants. METHODS: Pooled data from 1651 participants were used to explore dosing regimen (every 4 or every 8 weeks), demographic, viral, and pharmacokinetic covariates as potential predictors of CVF. Prior dosing regimen experience was accounted for using 2 populations. Two models were conducted in each population-baseline factor analyses exploring factors known at baseline and multivariable analyses exploring baseline factors plus postbaseline model-predicted CAB/RPV trough concentrations (4 and 44 weeks postinjection). Retained factors were evaluated to understand their contribution to CVF (alone or in combination). RESULTS: Overall, 1.4% (n = 23/1651) of participants had CVF through 152 weeks. The presence of RPV resistance-associated mutations, human immunodeficiency virus-1 subtype A6/A1, and body mass index ≥30 kg/m2 were associated with an increased risk of CVF (P < .05 adjusted incidence rate ratio), with participants with ≥2 of these baseline factors having a higher risk of CVF. Lower model-predicted CAB/RPV troughs were additional factors retained for multivariable analyses. CONCLUSIONS: The presence of ≥2 baseline factors (RPV resistance-associated mutations, A6/A1 subtype, and/or body mass index ≥30 kg/m2) was associated with increased CVF risk, consistent with prior analyses. Inclusion of initial model-predicted CAB/RPV trough concentrations (≤first quartile) did not improve the prediction of CVF beyond the presence of a combination of ≥2 baseline factors, reinforcing the clinical utility of the baseline factors in the appropriate use of CAB + RPV LA.
引用
- Orkin C, Schapiro JM, Perno CF, et al. Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure. Clin Infect Dis. 2023. PMID: 37340869. doi:10.1093/cid/ciad370
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。